Among them, the inhibitory activity of ODN A151 depends on the telomere sequence and phosphorothioate backbone to prevent cGAS activation by competing with DNA (Steinhagen et al., 2018), laying the foundation for developing new immunosuppressive agents to treat autoimmune diseases caused by cGAS abnormal activation. The gene discussed is CGAS; the disease is autoimmune disease.